The most extensively studied compounds are exenatide (Byetta [Amylin Pharmaceuticals, San Diego, CA], which has been approved by the US Food and Drug Administration [FDA] for the treatment of type 2 diabetes), liraglutide (Victoza [Novo Nordisk, Princeton, NJ], which has been submitted to the FDA for approval), sitaglitptin (Januvia [Abbott Laboratories, Abbott Park, IL], which has been approved by the FDA for type 2 diabetes), and vildagliptin (Galvus [Novo Nordisk, Princeton, NJ], which has been submitted to FDA)
& Bonefeld-Jrgensen, E
PMID 26131763
Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria
The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education